Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Williams, MD
Researcher Senior Vice President
Division of Hematology
Boston Children's Hospital
300 Longwood Avenue
Boston, Massachusetts, United States
Dr. Williams is the president of Dana-Farber Cancer and Blood Disorders Center. He also serves as Senior Vice President and Chief Scientific Officer at Boston Children’s Hospital and the Chief of Hematology/Oncology at Boston Children’s Hospital. He is also working as Leland Fikes Professor of Pediatrics at Harvard Medical School. His major research interests are – study of blood stem cell biology, blood formation, leukemia and the treatment of genetic blood diseases using gene therapy. Dr. Williams is originally trained in hematology/oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute. During his fellowship research at the MIT Cancer Center and the Whitehead Institute, he developed techniques that allowed for the introduction of genes into murine and human hematopoietic cells. Those techniques are still commonly utilized today. He has published over 250 peer-reviewed manuscripts and textbook chapters.
Representative Publications:
Sickle cell disease pain: II. Predicting health care use and activity level at 9-month follow-up
Pain drawings and sickle cell disease pain
Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype
+myBinderRelated Content
-
Robert H. Broyles, PhDRobert H. Broyles was founder and presid...
-
Data Brief: Healthcare Utilization for Vaso-Occlusive Episodes by People with Sickle Cell Disease in California and ...Many people with sickle cell disease (SC...
-
The Cellie Coping Kit helps sick kids manage the stress of treatmentDesigned by Marsac during her fellowship...
-
A Genome-Wide Association Study Identifies Blood Disorder–Related Variants Influencing Hemoglobin A1c With Implica...OBJECTIVE We aimed to identify hemoglobi...
-
Vivien Sheehan, MD, PhDDr. Vivien Sheehan is a pediatric and ad...
-
Hope for SCDHope for SCD strives to bridge the gap b...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
